Pharmaceuticals for covid19 treatment
AssigneeNantCell, Inc.
InventorsOleksandr BUZKO, Shiho TANAKA, Kayvan NIAZI
Life of this patent
Estimating the term…
Abstract
The present disclosure relates to methods of treatment for COVID19.
Claims21
A method of treating a SARS-CoV-2 virus infection in a subject in need thereof, the method comprising administering to the subject an effective amount of a pharmaceutical composition comprising a drug selected from the group consisting of piperacillin or a salt thereof, N-[4-[1-(1,4-dioxaspiro[4.5]dec-8-yl)-4-(8-oxa-3-azabicyclo[3.2.1]oct-3-yl)-1H-pyrazolo[3,4-d]pyrimidin-6-yl]phenyl]-N′-methylurea or a salt thereof, and cefoperazone or a salt thereof.
A method of treating a SARS-CoV-2 virus infection in a subject in need thereof, the method comprising administering to the subject an effective amount of a pharmaceutical composition comprising a drug selected from the group consisting of cilengitide or a salt thereof and hederacoside or a salt thereof.
A method of treating a SARS-CoV-2 virus infection in a subject in need thereof, the method comprising administering to the subject an effective amount of a pharmaceutical composition comprising a drug selected from the group consisting of (R,S)-ivosidenib or a salt thereof, evacetrapib or a salt thereof, idasanutlin or a salt thereof, and relugolix or a salt thereof.
Dependencies are inferred from the claim text.